BlueCrest Capital Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

BlueCrest Capital Management’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-5,006	Closed	-$262K	–	1490
2018 Q3	$262K	Buy	+5,006	New	+$273K	0.01%	1110
2018 Q2	–	Sell	-6,042	Closed	-$224K	–	1892
2018 Q1	$224K	Buy	+6,042	New	+$161K	0.01%	1232

Other funds holding GTHX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlueCrest Capital Management's GTHX Position: Q4 2018 in Review

BlueCrest Capital Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2018, closing a stake of 5,006 shares — an estimated $262K sold.

BlueCrest Capital Management first reported a position in GTHX in Q1 2018 and held it in 2 quarters. The position peaked at $262K in Q3 2018. 93 funds tracked by Wall St. Rank hold GTHX as of Q4 2018.

BlueCrest Capital Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
BlueCrest Capital Management sold 5,006 G1 Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $262K.
BlueCrest Capital Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
BlueCrest Capital Management's G1 Therapeutics, Inc. Common Stock position peaked at $262K in Q3 2018.
93 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.